An Efficacy, Safety and Tolerability Study of Ferrous Ascorbate and Folic Acid (Phosfomin-XT) in Iron Deficiency Anemia.
Loading...
Date
2012-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aim: This study was aimed to assess efficacy, safety and tolerability of combination of ferrous ascorbate and folic acid
(Phosfomin-XT) in patients with iron deficiency anemia (IDA). Settings and design: A total of 56 patients, who were between
18-55 years of age, with hemoglobin (Hb) 6-9 g/dl and serum ferritin <15 mg/l also complying with the inclusion and exclusion
criteria in the protocol were enrolled in the study after obtaining necessary approvals and informed consent. All were dispensed
with Phosfomin-XT fixed-dose combination (FDC) of ferrous ascorbate (equivalent to elemental iron 100 mg) + folic acid 1.5 mg
tablet once-daily after food for eight weeks. Patients were assessed at baseline and Weeks 2, 4, 6 and 8 for change in Hb level,
clinical evaluation and target Hb achievement. Results: Baseline mean Hb was 08.39 ± 0.75 g/dl, which significantly increased
to 9.76 ± 0.70 g/dl (16.3%) at Week 2 and further increased to 10.70 ± 0.70 g/dl (27.53%) at Week 4. At Week 6, it increased to
11.55 ± 0.67 g/dl (37.7%) and at Week 8, it increased to 12.53 ± 1.09 g/dl. Conclusions: The present study concludes that
Phosfomin-XT (ferrous ascorbate, equivalent to elemental iron 100 mg + folic acid 1.5 mg) tablet should be preferred as first
choice of oral iron salts to treat IDA due to positive effect on Hb value and superior tolerability.
Description
Keywords
Iron deficiency anemia, ferrous ascorbate, folic acid
Citation
Adsul B B, Mukaddam Qayum, Khandeparkar Prashant, Naik Manoj. An Efficacy, Safety and Tolerability Study of Ferrous Ascorbate and Folic Acid (Phosfomin-XT) in Iron Deficiency Anemia. Indian Journal of Clinical Practice. 2012 Apr; 22(11): 565-570.